Phillip George Febbo, MD
Year elected: 2009
Current membership category: Active
Associate Professor in ResidenceUniversity of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
Box 1711, Room A717
1600 Divisadero St.
San Francisco, CA 94115
United States of America
Prostate cancer is the most common non-cutaneous cancer and exhibits protean clinical manifestations from indolent and clinically insignificant to aggressive and lethal. I use genomic technologies and defined genetic and/or chemical perturbations to investigate prostate cancer biology and anticipate response to therapy using established prostate cancer cell lines, genetically-defined cell lines, prostate cancer mouse models, and clinical prostate cancer specimens. Some examples of discoveries from my work include being the first to publish a multi-gene expression-based predictor of prostate cancer recurrence after surgery, discovering decreased Hif pathway activity following mTOR inhibition, and identifying mechanisms of resistance associated with androgen ablation, docetaxel, imatinib, and mTOR inhibition. A unique aspect of my work has been a consistent focus on the incorporation of expression analysis into clinical trials. I have worked to create “learning loops” for prostate cancer clinical trials where the analysis of samples from one trial informs the design and implementation of subsequent clinical trials. Most recently, I am prospectively validating predictive, expression-based signatures for docetaxel, mTOR inhibition, and androgen receptor (AR) activity in metastatic prostate cancer. Our trial using a microarray-based signature of AR activity to determine therapy for men with metastatic prostate cancer will be the first trial to personalized care for men with prostate cancer based upon a molecular phenotype of their specific tumor and is emblematic of how we will improve and personalize care for the men diagnosed with this disease.